*Candida* species are the most common cause of healthcare-associated bloodstream infections \[[@OFV163C1]\], and *Candida glabrata* accounts for one third of all candidemia in the United States \[[@OFV163C2], [@OFV163C3]\]. Because *C glabrata* demonstrates increased resistance to the azole class of antifungal medications \[[@OFV163C4]\], echinocandins are the preferred treatment for this organism \[[@OFV163C5]\]. Echinocandins were first introduced in the early 2000s, and reports of resistance were rare until recently \[[@OFV163C6]\]. In the last few years, the Centers for Disease Control and Prevention (CDC) and others have reported increases in bloodstream infections caused by echinocandin and multidrug-resistant *Candida* species, the majority of which were *C glabrata* \[[@OFV163C2], [@OFV163C7]--[@OFV163C10]\].

Echinocandin resistance, thought to be acquired from prior exposure to echinocandins and mediated through mutations in the *FKS* genes \[[@OFV163C11]\], is problematic because there are few other options remaining for treatment of *C glabrata.* Alternative treatments such as amphotericin B are more toxic and often poorly tolerated \[[@OFV163C12]\]. Furthermore, testing for resistance to echinocandins is not routinely performed in most clinical laboratories, and therefore resistance may only be recognized when treatment failure occurs.

The objectives of this study were to describe the epidemiology of and risk factors for echinocandin nonsusceptible (NS) *C glabrata* bloodstream infections using data from a large, multisite, population-based surveillance program in the United States.

METHODS {#s2}
=======

The CDC\'s Emerging Infections Program conducts surveillance for *Candida* bloodstream infections in 4 metropolitan areas: Atlanta, Georgia (started in March 2008), Baltimore City and County, Maryland, (started in June 2008), the tri-county region of Portland Oregon (started in January 2011), and Knox County (Knoxville) and surrounding counties in Tennessee (started in January 2011); combined population is ∼7.9 million persons and includes 80 hospital sites. The methods of surveillance have been previously described \[[@OFV163C2]\]; in brief, a case of candidemia is defined as a blood culture positive for a *Candida* species collected from a resident of the surveillance area at least 30 days after any other blood culture positive for *Candida* species. Surveillance personnel use standardized case report forms to abstract demographic and clinical data from medical records. All available laboratory isolates are sent to the CDC for species confirmation and antifungal drug-susceptibility testing. *FKS* mutation analysis was performed on isolates that demonstrated elevated minimum inhibitory concentration (MIC) values during antifungal drug-susceptibility testing. Only cases with *C glabrata* infection that occurred during 2008--2014 and for which isolates were available for laboratory analysis are included in this report.

Laboratory Methods {#s2a}
------------------

Molecular identification of isolates at the CDC was conducted using a Luminex assay or DNA sequencing of the D1/D2 subunit of the 28S ribosomal DNA, as previously described \[[@OFV163C13]\]. Antifungal susceptibility testing was performed with broth microdilution with fluconazole, anidulafungin, caspofungin, and micafungin, according to the Clinical and Laboratory Standards Institute (CLSI) M27-A3 document guidelines \[[@OFV163C14]\], using frozen Roswell Park Memorial Institute (RPMI) microbroth trays custom manufactured by TREK Diagnostics (Cleveland, OH) with no indicator dye. Results were read after 24 hours, and the MIC was identified as the lowest concentration of drug that caused a significant decrease in growth compared with the control well. The mutations in hotspot-1 regions of *FKS1* and *FKS2* genes were detected by either the Luminex-based multiplex assay \[[@OFV163C15]\] or by DNA sequencing at the CDC as described previously \[[@OFV163C16]\].

Definitions {#s2b}
-----------

Isolates of *C glabrata* were categorized as susceptible, intermediate, or resistant to each echinocandin using the 2012 CLSI M27-S4 breakpoints \[[@OFV163C17]\]. Isolates with MICs in the intermediate or resistance range to 1 or more echinocandins were considered NS and are the focus of this analysis. For fluconazole, isolates with an MIC ≤ 32 μg/mL were considered susceptible dose-dependent, whereas those with an MIC of ≥64 μg/mL were considered resistant. Any isolate that was resistant to both fluconazole and 1 or more echinocandin was considered to be multidrug resistant. An isolate demonstrating mutations in the hotspot-1 regions of *FKS1* and *FKS2* genes was considered to have an *FKS* mutation.

Statistical Methods {#s2c}
-------------------

We used the Cochrane-Armitage test to assess longitudinal trends in the proportion of NS isolates. Categorical variables were analyzed using χ^2^ or Fisher\'s exact tests, and medians of continuous variables were analyzed using the Wilcoxon rank-sum test. Logistic regression analysis was applied to identify demographic and clinical variables associated with echinocandin nonsusceptibility and with having an *FKS* mutation. *FKS* mutation testing was not available for echinocandin susceptible isolates. Variables with a *P* \< .20 by bivariate analysis or were clinically relevant were included in multivariable model selection. Model selection was conducted using stepwise logistic regression and consideration of 2-way interaction terms. The level of significance was set at *α* = 0.05. All analyses were done using SAS software (version 9.3; SAS Institute, Inc., Cary, NC).

Human Subjects {#s2d}
--------------

The CDC ethics liaisons reviewed this surveillance project and deemed it a nonresearch activity. This activity was also evaluated individually at each surveillance location, and it was either deemed a public health assessment or human subjects research and then approved by local institutional review boards.

RESULTS {#s3}
=======

There were 1591 reported cases of *C glabrata* infections during 2008--2014 in the 4 surveillance sites; 1385 (87%) cases with isolates and clinical information were available and included in analysis. There were no significant differences in demographic characteristics of cases with and without available isolates. Of these 1385 cases, 6.0% (n = 83) had isolates that were NS to echinocandins (1.4% \[n = 19\] intermediate, 4.6% \[n = 64\] resistant to 1 or more echinocandin). Susceptibility varied by echinocandin: 4.8% (n = 66) of cases had isolates that were NS to micafungin (13 intermediate and 53 resistant), 4.0% (n = 55) were NS to caspofungin (17 intermediate and 38 resistant), and 3.7% (n = 51) were NS to anidulafungin (6 intermediate and 45 resistant); 2.9% (n = 40) were NS to all 3 echinocandins, and 2.1% (n = 29) were resistant to all 3 echinocandins. Isolates with fluconazole resistance were detected in 9.6% of cases (n = 132), and multidrug resistance was detected in 1.7% (n = 23).

Time and Location Trends {#s3a}
------------------------

The proportion of cases with an echinocandin-NS *C glabrata* isolate increased over time: 4.2% (7 of 161) of isolates in 2008 were NS, compared with 7.8% (13 of 153) in 2014 (test for trend: *P* \< .001) (Figure [1](#OFV163F1){ref-type="fig"}). The surveillance area in Georgia had the highest proportion of cases with NS isolates (6.9%; 43 of 620), followed by the Maryland surveillance area (5.9%; 35 of 598), the Oregon surveillance area (3.0%; 2 of 67), and the Tennessee surveillance area (3.0%; 3 of 100). All surveillance areas had an increase in proportion of NS cases with the Georgia surveillance area experiencing the highest increase from 3.4% (3 of 89) in 2008 to 14.5% (9 of 62) in 2014 (Figure [1](#OFV163F1){ref-type="fig"}). Figure 1.Proportion of cases with *Candida glabrata* isolates that were nonsusceptible to echinocandins, by surveillance site and year, 2008--2014. Surveillance areas: Atlanta metropolitan area, Georgia (\[GA\] started in March 2008), Baltimore City and County, Maryland (\[MD\] started in June 2008), Tri-county region of Portland Oregon (\[OR\] started in January 2011), and Knoxville, Tennessee (\[TN\] started in January 2011); combined population is 7.9 million persons and includes 80 hospital sites.

Among the 80 hospitals within all 4 surveillance areas, *C glabrata* isolates were identified at 57 (71.3%); the number ranged from 1 to 143 (median, 12). Twenty-three (40.3%) of these 57 hospitals had any cases with NS *C glabrata*. Among the 21 hospitals that submitted at least 20 *C glabrata* isolates during the study period, the proportion of NS isolates identified ranged from 0%--25.8% (Figure [2](#OFV163F2){ref-type="fig"}). Three large, academic hospitals accounted for nearly half (n = 40 of 83) of all cases with NS isolates. Figure 2.Proportion of *Candida glabrata* cases with echinocandin nonsusceptible (NS) isolates by hospital site (among hospitals with ≥20 isolates submitted during the study period), 2008--2014, sorted by proportion of NS isolates.

Factors Associated With Candidemia Caused by Echinocandin Nonsusceptible *Candida glabrata* {#s3b}
-------------------------------------------------------------------------------------------

### Univariable Analyses {#s3b1}

The proportion of cases with NS isolates was significantly different by age category (*P* \< .001) (Table [1](#OFV163TB1){ref-type="table"}). Cases with NS isolates were also more likely to have had a prior hospitalization in the 90 days before *C glabrata*-positive blood culture (echinocandin NS: 78.3% vs susceptible: 59.1%; *P* \< .001), have received total parenteral nutrition in the 14 days before having *C glabrata*-positive blood culture (NS: 41.0% vs susceptible: 26.9%; *P* = .008), or have had a previous episode of candidemia (NS: 40.2% vs susceptible: 7.6%; *P* \< .001). Cases with NS isolates were also more likely to have ever received an echinocandin (NS: 38.6% vs susceptible: 5.2%; *P* \< .001) and have isolates with fluconazole resistance (NS: 32.9% vs susceptible: 8.1%; *P* \< .001). Cases with NS isolates were in the hospital for a median duration of 7 days (interquartile range \[IQR\]: 0--20.5) before candidemia diagnosis compared with 5 days (IQR: 0--15) for cases with susceptible isolates (*P* = .30). There were no significant differences between those with echinocandin susceptible and NS isolates by sex, race (black vs non-black), presence of certain underlying conditions, including diabetes, underlying liver disease, cancer, renal disease, organ transplantation, or abdominal surgery in the 90 days before *C glabrata*-positive blood culture. Residence in a nursing home at the time of *C glabrata*-positive blood culture, intensive care unit stay, presence of a central venous catheter in the 2 days before *C glabrata*-positive blood culture, and 30-day mortality were also not significantly different between the 2 groups. Table 1.Characteristics of Patients With *Candida glabrata* Candidemia by Echinocandin SusceptibilityCharacteristicEchinocandin Nonsusceptible, n (%)Echinocandin Susceptible, n (%)*P* Value^a^Total: n = 133483 (6.0)1302 (94.0)**\<.001**Age in years 0--10 (0)15 (1.2) 2--172 (2.4)7 (0.5) 18--4428 (33.7)187 (14.5) 45--6425 (30.1)531 (41.1) ≥6528 (33.7)552 (42.7)Female sex39 (47.6)675 (52.0).494Black race43 (54.4)688 (54.9)\>.999Underlying liver condition10 (12.1)191(14.7).630Diabetes35 (42.2)525 (40.3).731Abdominal surgery in the 90 days prior to candidemia18 (21.7)252 (19.4).668Previous hospitalization in the 90 days prior to candidemia65 (78.3)729 (59.1)**\<.001**Nursing home resident at the time of candidemia23 (30.3)293 (25.5).347Intensive care unit admission for candidemia51 (62.2)815 (64.1).723Central venous catheter present in the 2 days prior to candidemia70 (86.4)947 (76.8).054Total parenteral nutrition in the 14 days prior to candidemia34 (41.0)350 (26.9)**.008**Previous candidemia episode33 (40.2)98 (7.6)**\<.001**Ever received echinocandin32 (38.6)68 (5.2)**\<.001**Fluconazole-resistant isolate27 (32.9)105 (8.1)**\<.001**Number of days in the hospital before candidemia, median (IQR)7 (0--15)5 (0--20.5).303^b^Death within 30 days of candidemia18 (21.7)357 (27.5).308[^1][^2][^3][^4]

### Multivariable Analyses {#s3b2}

Table [2](#OFV163TB2){ref-type="table"} shows the unadjusted and adjusted odds ratios for variables included in the multivariable model selection step. In the multivariable analysis, factors that remained independently associated with having a NS isolate were as follows: hospitalization in the 90 days before candidemia (adjusted odds ratio \[aOR\], 1.9; 95% confidence interval \[CI\], 1.0--3.4), previous episode of candidemia (aOR, 2.5; 95% CI, 1.5--5.1), prior exposure to echinocandins (aOR, 5.3; 95% CI, 2.6--10.8), and fluconazole resistance (aOR, 3.6; 95% CI, 2.0--6.4) (Table [2](#OFV163TB2){ref-type="table"}). Table 2.Risk Factors for Echinocandin nonsusceptible *Candida glabrata* Infection and Presence of *FKS* Mutations Using Multivariable ModelingCharacteristicNonsusceptible*FKS* MutationsUnadjusted Odds Ratio (95% CI)Adjusted Odd Ratio (95% CI)Unadjusted Odds Ratio (95% CI)Adjusted Odd Ratio (95% CI)Age 0--171.7 (.4--8.0)1.7 (.4--8.6)3.6 (.4--31.3)3.9 (.4--37.9) 18--443.0 (1.7--5.1)1.7 (.9--3.3)6.5 (2.9--14.7)4.4 (1.6--11.8) 45--640.9 (.5--1.6)0.6 (.3--1.2)1.2 (.5--2.9)0.8 (.3--2.2) ≥65ReferenceReferenceReferenceReferenceHospitalization in prior 90 days2.5 (1.5--4.3)1.9 (1.1--3.5)2.8 (1.3--6.0)5.9 (1.7--20.6)Previous candidemia8.2 (5.0--13.3)2.5 (1.3--5.1)11.1 (5.8--21.5)1.6 (.6--4.4)Prior echinocandin11.4 (6.8--18.9)5.3 (2.6--10.8)18.9 (9.7--37.2)11.6 (4.4--31.3)Fluconazole resistance5.6 (3.4--9.2)3.6 (2.0--6.4)6.0 (3.1--11.8)3.2 (1.4--7.2)Time between admission and *Candida* culture date (per week)1.1 (1.0--1.1)Not selected to remain in the model1.1 (1.1--1.2)1.2 (1.1--1.3)Received TPN1.9 (1.2--3.0)Not selected to remain in the model3.0 (1.6--5.8)Not selected to remain in the modelCentral venous catheter2.0 (1.01--3.9)Not selected to remain in the model4.8 (1.2--20.2)Not selected to remain in the model[^5]

We also examined factors associated with nonsusceptibility to caspofungin and micafungin/anidulafungin separately. Results of this analysis are presented in a supplementary table ([Supplementary Table S1](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofv163/-/DC1)). Risk factors for nonsusceptibility for each of the echinocandins were largely the same as risk factors for nonsusceptibility to any echinocandin. However, there was a stronger association between prior echinocandin exposure and caspofungin nonsusceptibility than to micafungin/anidulafungin nonsusceptibility (aOR 8.3 \[95% CI, 3.7--18.8\] for caspofungin vs aOR 4.9 \[95% CI, 2.3--10.3\] for micafungin/anidulafungin).

*FKS* Mutations {#s3c}
---------------

Testing for *FKS* mutation was performed on 859 of 1302 (66.0%) of susceptible isolates and 73 of 83 (88.0%) NS isolates. None of the isolates that were categorized as susceptible had *FKS* mutations, and 41 (56.2%) of isolates categorized as NS had *FKS* mutations present. Among resistant isolates, 70% (41 of 58) had an *FKS* mutation present, whereas none of the intermediate isolates (0 of 15) had *FKS* mutations. Among the 28 cases that had an isolate resistant to all 3 echinocandins by MIC values, 92.9% (n = 26) had an *FKS* mutation.

Risk factors for having *FKS* mutations were evaluated using the 932 cases with *FKS* mutation testing performed. Risk factors were similar to those for having an NS isolate (Table [2](#OFV163TB2){ref-type="table"}). An exception was that previous candidemia episode was not an independent risk factor for having an FKS mutation but remained in the multivariable model as a confounder. In addition, a new variable, time between admission and *C glabrata-*positive blood culture, was selected to remain in the model, and this was associated with a 16% higher odds of an isolate with a *FKS* mutation for every week spent in the hospital (aOR, 1.16; 95% CI, 1.06--1.26).

Resistance Without Any Prior Antifungal Drug Exposure {#s3d}
-----------------------------------------------------

Of the 83 cases with NS isolates*,* more than half (59%; n = 51) did not have a known prior echinocandin exposure and 48.2% (n = 40) did not have known prior echinocandin exposure or a known previous episode of candidemia. Forty-four percent (18 of 41) of cases with *FKS* mutations did not have any known echinocandin exposure, and 37% (15 of 41) did not have any known echinocandin exposure or known previous episode of candidemia.

DISCUSSION {#s4}
==========

In this large population-based surveillance program, we found that isolates NS to echinocandins were recovered from 6% of cases of *C glabrata* candidemia. Furthermore, the proportion of cases with NS isolates has increased in all surveillance areas, despite demonstration that the total incidence of candidemia, including *C glabrata* candidemia, is declining in the United States \[[@OFV163C7]\]. An equally important finding is that nonsusceptibility was not uniformly distributed across hospitals. There were many hospitals with zero or only a few cases with echinocandin NS *C glabrata* isolates, whereas at some hospitals, 1 of every 6 *C glabrata* cases had an isolate with echinocandin MICs in the NS range.

The difference in the proportion of NS isolates by hospital site may be due to differences in echinocandin utilization by hospital \[[@OFV163C18]\]. Echinocandin utilization is likely to vary both by patient population and acuity. For instance, because echinocandins are the recommended first-line treatment for candidemia in cancer patients with neutropenia \[[@OFV163C5]\], hospitals with higher numbers of neutropenic cancer patients are likely to use more echinocandins than hospitals without such populations. Echinocandin use may also be influenced by hospital antimicrobial stewardship policies \[[@OFV163C19], [@OFV163C20]\]. Different strategies may be required to control the rise of echinocandin resistance, depending on the prevalence of NS *C glabrata* isolates in any given facility. All hospitals would likely benefit from a strong antimicrobial stewardship program that includes antifungal drugs \[[@OFV163C21]\]. In addition, hospitals that already have a substantial burden of echinocandin NS isolates should consider routine echinocandin susceptibility testing to identify patients who are at risk for antifungal treatment failure before clinical failure occurs.

Prior exposure to echinocandins was strongly associated with having infection with a NS isolate in this analysis, a finding that is consistent with prior studies \[[@OFV163C8], [@OFV163C10], [@OFV163C22]\]. Prior exposure likely results in selection pressure and facilitates generation and persistence of resistant isolates. We were surprised to find that more than half of cases with an NS isolate did not have known echinocandin exposure. In addition, 40% of isolates with *FKS* mutations did not come from patients with known prior echinocandin exposure. Lack of echinocandin exposure among those with echinocandin-resistant isolates has also been noted in at least 1 other study \[[@OFV163C10]\]. Although the data are limited by incomplete information on dose, duration, and sequence of antifungal therapy, the finding that patients without a prior history of echinocandin exposure had echinocandin NS isolates raises the possibility that resistance is not just acquired from prior exposure to echinocandins, but that NS organisms may also be transmitted within medical and community settings.

The clustering of cases with NS isolates at relatively few hospitals could also be explained by circulation of NS isolates either in the hospital or in the community that the hospital serves. The finding that each additional week in the hospital before the *C glabrata-*positive blood culture independently raised the odds of having an NS isolate and an *FKS* mutation suggests that resistant isolates may be transmitted in hospitals. The possibility of transmission could be further evaluated by studying relationships of NS isolates via whole genome sequencing in the same hospital over a short period of time.

Fluconazole resistance was associated with echinocandin nonsusceptibility in this study and has been reported in other studies \[[@OFV163C9], [@OFV163C10]\]. Resistance to azoles in isolates of *C glabrata* is a result of overexpression of *Candida* drug resistance efflux pumps \[[@OFV163C23]\], which are not involved in echinocandin resistance, although *C glabrata* is thought to be unique in its ability to sequentially acquire and express unlinked resistance-conferring mutations \[[@OFV163C8]\]. It is notable that we observed multidrug resistance in approximately 2% of *C glabrata* isolates. Previous candidemia was independently associated with having an NS isolate, even after controlling for prior exposure to echinocandins and fluconazole resistance. It is possible that fluconazole treatment of previous *C glabrata* candidemia exerts selection pressure, resulting in genomic changes in the pathogen even in the absence of overt fluconazole resistance. Such organisms may persist as colonizers in patients and, if subsequently exposed to antifungal drugs, emerge as NS to echinocandins \[[@OFV163C23]\].

Older age has been shown to be a risk factor for candidemia itself \[[@OFV163C2]\] and for colonization with *C glabrata* \[[@OFV163C24]\], but not necessarily for resistant infection. In this analysis, we found that in fact, younger age group of 18--44 years was associated with higher odds having an echinocandin NS isolate compared with the ≥65 years age group. Other investigators have also reported similar findings with fluconazole resistance; Pfaller et al \[[@OFV163C25]\], reported that although adults over the age of 60 were more likely to have candidemia with *C glabrata*, they were less likely to have an isolate resistant to fluconazole than adults aged 20--59. It is possible that differences in underlying conditions (eg, bone marrow transplantation is more common in younger adults and is associated with receipt of antifungal prophylaxis, which in turn may result in development of resistance) and mode of acquisition of *C glabrata* infection (colonization more likely in older adults) may account for differences in proportion of echinocandin NS isolates seen in the various age groups.

We conducted a separate analysis examining risk factors for *FKS* mutations because presence of these mutations is more closely correlated with treatment failure than elevated echinocandin MICs \[[@OFV163C26]\]. The associations we found were largely the same as those found for NS isolates, although the strength of the association was higher for those with *FKS* mutations. This suggests that the associations identified by this analysis can be used in the clinical setting to identify not only patients at high risk for echinocandin NS *C glabrata* infection, but also those at risk for potential treatment failure based on presence of *FKS* mutations.

There are several limitations to this study. First, although we did re-evaluate the medical records for a subset of patients with echinocandin-resistant infections and no known prior echinocandin exposure to confirm lack of echinocandin exposure, it is possible that presence of risk factors such as previous candidemia episodes and prior exposures to echinocandins were missed. We would be less likely to miss such information than a single-center study because the surveillance system includes all hospitals within the catchment area. This means that previous episodes of candidemia and associated treatment data would be captured even if infections were detected at another hospital in the surveillance system. Second, we did not collect dates, duration, dose, or sequence of antifungal therapy at all sites for all years of the study and were therefore unable to study treatment failure or duration of echinocandin therapy prior to resistance development; this limitation is somewhat allayed by previous studies demonstrating that echinocandin treatment failure is associated with presence of an *FKS* mutation \[[@OFV163C8]\]. Although this study is population-based surveillance, findings from these surveillance areas may not be generalizable to the entire United States. Hospitals are deidentified in the surveillance system. Therefore, we do not have details on patient populations treated and echinocandin usage patterns at the 3 hospitals with a high burden of NS isolates compared with other hospital with a lower proportion of NS isolates. This information would shed more light on hospital-level factors associated with echinocandin nonsusceptibility.

CONCLUSION**S** {#s5}
===============

Increases in echinocandin NS *C glabrata* infections are concerning due to limited treatment options. Although currently NS isolates seem to be concentrated in a small number of hospitals, increased use of echinocandins may result in more widespread resistance. There is an urgent need for antifungal resistance control measures to prevent further increases in echinocandin NS *C glabrata.* A better understanding of how nonsusceptibility is acquired, including whether echinocandin resistance is transmitted between patients, is important to guide infection prevention measures.

Supplementary Data {#s6}
==================

[Supplementary material](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofv163/-/DC1) is available online at *Open Forum Infectious Diseases* online (<http://OpenForumInfectiousDiseases.oxfordjournals.org/>).
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[^1]: The significant *P* Values are indicated in bold.

[^2]: Abbreviation: IQR, interquartile range.

[^3]: ^a^ Fishers exact test.

[^4]: ^b^ Wilcoxon rank-sum test.

[^5]: Abbreviations: CI, confidence interval; TPN, total parenteral nutrition.
